ML in Gene Therapy

Engineering AAV when the search space is the problem

Ravi Kalia

Four Sequences That Worked

Four medicines. Each works because someone chose the sequence.

Vaccine 1: A Virus as Van

A chimp cold virus (adenovirus), emptied and reloaded.

  • Growth gene removed, spike gene added
  • It can no longer copy itself

≈35 kb of DNA (35,000 letters)

The virus is the courier, not the medicine.

The gene it carries was written, not discovered.

Photograph of a chimpanzee.

Source of the virus

Photograph of a white delivery van.

The van: a courier, not the medicine

Voysey et al. (2021)

Vaccine 2: No Virus at All

Just the message, wrapped in a fat bubble.

  • mRNA with one building block swapped
  • Fat droplet carries it into cells

4,284 nucleotides

Cross-section of a lipid nanoparticle: strands of nucleic acid held inside a shell of PEG-lipid, ionizable lipid, helper lipid and cholesterol.

Designed in days from the virus genome.

Portrait of Uğur Şahin

Uğur ŞahinBioNTech

Portrait of Özlem Türeci

Özlem TüreciBioNTech

Polack et al. (2020)

One Swap Calms the Cell

Your innate immune system treats plain mRNA as infection and destroys it.

Swapping every uridine for N1-methylpseudouridine quiets the alarm.

Same message, different chemistry: the alarm stays quiet.

Portrait of Katalin Karikó

Katalin Karikówith Drew Weissman — Nobel Prize, 2023

Polack et al. (2020)

Muscular Dystrophy: A Gene Cut to Fit

Duchenne muscular dystrophy: muscle breaks down without dystrophin.

  • A virus (AAV) carries the gene to muscle
  • A shortened dystrophin
  • The full gene (11 kb) does not fit

≈5 kb cassette: gene plus switch

Nineteenth-century engraving showing calf pseudohypertrophy in a child with Duchenne muscular dystrophy.

Calf swelling, from Duchenne’s 1868 plates.

The van is fixed. The cargo was redesigned.

Mendell et al. (2023)

Cancer Antibody: The Odd One Out

No virus: a protein made in cultured cells.

  • Blocks PD-1, a brake on T cells
  • Mouse binding regions on a human frame

≈1.4 kb of coding sequence

Portrait photograph of Jimmy Carter, taken in 2014.

Jimmy CarterAnnounced metastatic melanoma in August 2015; clear scans by December

Spread melanoma, treated with surgery, radiosurgery and this antibody.

The product is a protein. The asset is the sequence.

Emancipator (2020); Goldberg et al. (2016)

Four Sequences, Same Scale

Length does not predict impact. The design problem is the same.

The Virus Worth Borrowing

AAV cannot copy itself alone. That defect is why we use it.

Success 1: Blindness

Problem. Without the RPE65 gene, light-sensing cells die.

AAV carries. A working RPE65 copy, injected under the retina. Luxturna, 2017.

Result. People could cross an obstacle course in dim light again.

First US-approved gene therapy for an inherited disease.

Photograph of the back of the eye showing a retina in advanced degeneration, with dark pigment clumps and thinned vessels.

A retina in advanced degeneration. Photo: Christian Hamel, CC BY 2.0.

U.S. Food and Drug Administration (2026a)

Success 2: Weak Muscles

Problem. Without SMN1, the nerves that move muscles die.

AAV carries. A working SMN1 gene, in one drip into a vein. Zolgensma, 2019.

Result. Treated babies have sat up, and many have walked.

One drip, not lifelong treatment.

Diagram of motor neurons in the spinal cord sending nerves to groups of muscle fibres.

Nerve cells in the spinal cord drive muscles. Diagram: Walsh and Sved, CC BY-SA 4.0.

U.S. Food and Drug Administration (2026a)

Success 3: Blood That Cannot Clot

Problem. In haemophilia B, the liver lacks clotting factor IX.

AAV carries. A working factor IX gene, in one drip. The liver makes the protein. Hemgenix, 2022.

Result. Bleeding fell and most people stopped regular injections.

The patient’s own liver becomes the factory.

Photograph of two vials of freeze-dried clotting factor concentrate for haemophilia.

Clotting-factor concentrate, the lifelong infusion gene therapy aims to replace. Photo: JJEv810, CC BY-SA 4.0.

U.S. Food and Drug Administration (2026a)

Success 4: Deafness

Problem. Without OTOF, ear cells cannot signal to the brain.

AAV carries. A working OTOF gene, split across two viruses, into the cochlea. Otarmeni, 2026.

Result. Children who had never heard began to hear speech.

First approved treatment for genetic deafness.

Labelled cross-section diagram of the human ear showing the outer ear, middle ear and the spiral-shaped cochlea.

The cochlea is the spiral in the inner ear. Diagram: Chittka and Brockmann, CC BY 2.5.

U.S. Food and Drug Administration (2026a)

What Is a Virus?

A virus is instructions in a protein shell.

  • Shell: protects and sticks to a cell
  • Instructions: DNA or RNA
  • No machinery: it borrows yours

A virus is a delivery van carrying instructions.

AAV Up Close

  • DNA genome of 4.7 kb
  • Shell (capsid) of 60 protein pieces
  • About 26 nm across
  • No known disease in humans

Drag it.

Xie et al. (2002)

Where the Symmetry Is

Sixty identical pieces, arranged like a 20-sided ball.

  • 5-fold ×6: a channel
  • 3-fold ×10: the spikes
  • 2-fold ×15: a dip

Xie et al. (2002)

From DNA to Protein

DNA
the stored copy

RNA
a working copy

Amino acids
one per codon

Protein
the folded machine

Same colours, same codons: DNA is read into RNA, RNA into amino acids, and the chain folds.

The Genome at a Glance

Scale map of the wild-type AAV2 genome showing the two ITRs, the p5, p19 and p40 promoters, the rep and cap open reading frames, and the nested AAP and MAAP accessory reading frames.

Two genes: rep copies and packages. cap builds the shell. Short DNA hairpins (ITRs) mark each end.

Samulski and Muzyczka (2014)

Rep Proteins We Throw Away

Rep78 and Rep68

Start copying. They can also insert viral DNA at one spot on chromosome 19.

Rep52 and Rep40

Motors that pull the genome into the shell.

The numbers are sizes in kilodaltons.

Delete rep and the virus loses its fixed insertion site.

Kotin et al. (1990)

Three Shell Proteins

One gene, three versions.

VP1 87 kDa has a membrane-breaking tail
VP2 73 kDa not essential
VP3 62 kDa most of the shell

Ratio about 1 : 1 : 10.

Five VP1 copies let the virus escape the endosome.

Girod et al. (2002)

Two Hidden Genes

AAP

Hidden inside cap. Helps build the shell.

MAAP

A different reading frame of the same DNA. Helps the virus leave the cell.

A 2019 mutation scan revealed MAAP.

A gene nobody had spotted emerged from the data.

Sonntag et al. (2010); Ogden et al. (2019)

Defective by Design

AAV needs a helper virus to copy itself.

Adenovirus, a cold virus, can help.

Herpes simplex virus can too.

For medicine, this is a feature:

  • In the lab, helper genes come on a plasmid (a small DNA circle)
  • A vector that cannot copy cannot spread

Not copying itself is the safety feature.

Samulski and Muzyczka (2014)

Why Not Adenovirus?

Good vaccine

  • Carries a larger gene
  • Strong gene expression
  • Strong immune response

Poor gene therapy

  • Immune system kills treated cells
  • Many people already have antibodies
  • Inflammation at therapeutic doses

A vaccine wants an immune response. Gene therapy does not.

Dunbar et al. (2018)

Serotypes: Same Shell, New Surface

Same fold, same 60 pieces. Only the outer loops differ.

  • AAV2 sticks to heparan sulfate
  • AAV9 sticks to galactose

Surface loops decide which tissue a virus reaches.

Xie et al. (2002); DiMattia et al. (2012); Summerford and Samulski (1998); Shen et al. (2011)

From Virus to Vector

A vector is a virus rebuilt as a delivery van. Every viral gene goes. Only the end “handles” stay.

Keep Only the End Handles

Two recombinant AAV expression cassettes drawn to scale against the 4.7 kb packaging limit, with Factor IX, micro-dystrophin and B-domain-deleted Factor VIII coding sequences drawn to the same scale.

Gray et al. (2011); Zanta-Boussif et al. (2009)

Size Decides the Medicine

Gene to deliver Size Fits?
Factor IX (clotting protein) 1.4 kb easily
micro-dystrophin (short muscle protein) 3.8 kb just
Factor VIII (trimmed clotting protein) 4.4 kb no room left
dystrophin (full length) 11 kb never

Duchenne therapy uses a shrunken “micro” dystrophin. Haemophilia A is harder to treat than B.

A shell’s size limit shapes the medicine.

Mendell et al. (2023)

What the Limit Produced

Product Delivery virus Gene delivered Where it is given
Zolgensma (2019) AAV9 SMN1 0.9 kb into a vein
Itvisma (2025) AAV9 SMN1 0.9 kb into spinal fluid
Hemgenix (2022) AAV5 F9 Padua 1.4 kb into a vein
Kebilidi (2024) AAV2 DDC 1.4 kb into the brain
Fayuvi (2026) AAV9 SGSH 1.5 kb into a vein
Luxturna (2017) AAV2 RPE65 1.6 kb under the retina
Elevidys (2023) AAVrh74 micro-dystrophin 3.8 kb into a vein
Otarmeni (2026) AAV1 × 2 OTOF 6.0 kb into the inner ear

Sorted by gene size. Only the last is too big.

OTOF is 6 kb, so it is split across two vectors. The cell stitches it back together.

The limit did not move. The design did.

U.S. Food and Drug Administration (2026a); U.S. Food and Drug Administration (2026b)

Getting In

Between injection and a working gene, most of the dose is lost.

From Needle to Cell

The journey of an AAV dose from the infusion needle to the target cell in four magnifications — infusion into a vein, circulation where antibodies and liver and spleen clearance remove most of the dose, extravasation across the vessel wall, and arrival at the cell surface — with a tapering band showing the surviving fraction collapsing at every stage.

Mingozzi and High (2013)

The Journey In

Girod et al. (2002); Cataldi and McCarty (2010); Nakai et al. (2001)

What Happens to the DNA

  • Cell copies the second strand
  • Repair enzymes join the ends into circles
  • Histones wrap the circles

The cell still notices this DNA.

Nakai et al. (2001)

From Hairpin to Chromatin

The fate of the delivered AAV genome: the released single strand with its T-shaped ITR hairpins is made double-stranded, host repair can join ITR ends into circular monomers and concatemers, and the circle is wrapped in host nucleosomes into a chromatinised episome that RNA polymerase II transcribes into mRNA and the ribosome translates into the therapeutic protein.

Nakai et al. (2001)

Why Expression Fades

The circle is not copied when the cell divides.

Non-dividing cells (neurons, muscle): circles can last.

Dividing cells (a child’s liver): the vector is diluted.

The price of deleting rep, the gene that let the virus integrate.

Safety gained; permanence lost.

Lasting for decades is untested.

Nakai et al. (2001)

Making It at Scale

One patient needs trillions of virus particles. That is a factory job.

Two Ways to Grow the Virus

HEK293 triple transfection compared with the Sf9 baculovirus expression system, showing the genetic components each platform delivers and a comparison of scale, yield and capsid protein modification.

Urabe et al. (2002)

Henrietta Lacks: Where Cell Lines Began

1951, Baltimore. Henrietta Lacks, 31, is treated for cervical cancer. A doctor takes a tumour sample. Nobody asks her.

Her cells kept dividing in a dish. They became HeLa.

The first human cells that would not die.

Close-up of the bronze statue of Henrietta Lacks in Bristol, showing her face in profile.

Statue of Henrietta Lacks, Bristol. Photo: 14GTR, CC BY-SA 4.0.

False-colour scanning electron micrograph of a HeLa cell with long filaments spreading across the surface beneath it.

A HeLa cell, scanning electron micrograph. Photo: NIH, public domain.

Purifying the Virus in Three Steps

The rAAV downstream purification train — clarification, camelid VHH affinity capture, anion exchange polishing to separate full from empty capsids, and tangential flow filtration — followed by the critical quality attributes.

Mingozzi and High (2013)

Why Empty Capsids Matter

An empty capsid is a shell with no gene. The body still sees it.

  • Foreign protein for immunity to attack
  • Uses up the patient’s tolerance
  • Counts towards the dose

Every batch is checked for full versus empty shells.

Foreign protein, no benefit.

Mingozzi and High (2013)

The Dose Ceiling

A bigger dose works better, but harms more.

The Therapeutic Window

The systemic rAAV therapeutic window, with efficacy and toxicity curves against dose, neutralising antibodies excluding patients at the low end, and capsid T cell responses, complement activation, hepatotoxicity, thrombotic microangiopathy and dorsal root ganglion toxicity bounding the high end.

Manno et al. (2006); Hinderer et al. (2018)

Three Ways the Dose Fails

Before treatment

Neutralising antibodies block the virus. These patients cannot be treated.

At the right dose

Killer T cells destroy liver cells showing viral protein. Gene expression falls.

Above the right dose

Complement (blood proteins that attack foreign surfaces), plus liver and nerve damage.

Mingozzi and High (2013); Faust et al. (2013); Hinderer et al. (2018)

Engineering the Modules

We can redesign three parts of a gene therapy vector: the shell, the switch and the DNA ends.

Three Parts, Three Problems

Surface of the AAV2 capsid, computed from crystal structure 1LP3, with one five-fold axis centred.

Capsid

The protein shell. It picks the target cells and dodges antibodies.

A protein-surface problem.

Diagram of an enhancer looping DNA so that activators and general transcription factors sit on the promoter and RNA polymerase starts the gene.

Promoter

The DNA switch. It sets where, and how strongly, the gene turns on.

A gene-regulation problem.

Base-by-base diagram of the AAV inverted terminal repeat folded into a T-shaped hairpin, in its flop and flip forms.

ITR

Short DNA repeats at both ends. They help packaging and persistence.

A DNA-shape problem.

The Search Space Is Huge

The capsid protein has 735 amino acids. Each can be one of 20.

A 60-residue stretch alone has about 10⁷⁸ possible sequences.

Nine orange peaks are measured natural capsids. The rest is untested.

Romero and Arnold (2009)

Capsid Shuffling

Parent genes are cut up and reassembled. Each colour is one parent.

Cut up several natural capsid genes. Let them reassemble as mosaics. Keep the ones that work.

Grimm et al. (2008)

What Shuffling Gave Us

Capsid shuffling in four stages: the cap genes of nine natural serotypes are digested into fragments, the fragments prime on one another and reassemble into a library of chimeras whose coloured blocks show which parent contributed each stretch, and selection returns a single survivor, AAV-DJ, a mosaic of AAV2, AAV8 and AAV9. A panel notes that what you do not get is any function mapping sequence to fitness.

Grimm et al. (2008)

One Loop, a Billion Variants

Peptide display in four stages: a random 7-mer is inserted into the VR-VIII loop at residue 588 of AAV9, giving 20⁷ ≈ 1.3 billion variants; the library is injected and recovered from the target tissue; the enriched sequence TLAVPFK defines AAV-PHP.B, which crosses the mouse blood-brain barrier about 40-fold better than AAV9. A band underneath notes the advantage runs through Ly6a, a mouse protein with no functional primate equivalent.

It worked in mice. Mice were the wrong model.

Deverman et al. (2016)

What Is a Model?

Model: a rule learned from examples that predicts.

Training: adjusting the rule to fit the examples.

Testing: checking it on examples it has never seen.

How a Random Forest Predicts

Follow one variant down three trees. Do they agree?

Breiman (2001)

From Mouse to Macaque

Fit4Function: one model per measurable property.

Six properties, combined.

88% of designed variants met all six.

No one predictor carries across species. All six together do.

Eid et al. (2024)

Predict Fitness Before Measuring

Can 3D structure alone predict how well a capsid is produced?

No measured AAV data was used to train.

Threefold more mutations beat the natural capsid than random ones. Preprint.

A capsid you cannot make is no medicine.

All of this can be calculated from a structure.

Mikos et al. (2021)

Score or Propose?

Discriminative versus generative models over sequence space. A discriminative model learns P(Y|X): it draws a boundary through the small labelled region and has uncertain predictions outside its training distribution. A generative model learns P(X), a distribution over training sequences, from sequences without phenotype labels, and new candidates can be sampled from it. A pipeline underneath shows the combination: generate candidates, score them, measure only the survivors.

Ng and Jordan (2001)

What a VAE Does

A VAE squeezes, then rebuilds.

Encoder: sequence to a few numbers.

Decoder: numbers back to a sequence.

Move the marker: the sequence changes smoothly.

Ng and Jordan (2001); Bryant et al. (2021)

Models That Design Proteins

A generative model learns patterns from many examples, then writes new ones that fit.

Like autocomplete for proteins.

The examples are sequences nature already made.

The model proposes new ones.

Data matters more than the type of model.

Bryant et al. (2021)

Mutate Everything, Measure Everything

Deep mutational scanning compared with directed evolution. A comprehensive library containing every variant goes through one selection; the population is sequenced before and after, and each variant's fitness is the log ratio of its counts, so enrichment and depletion can be estimated for adequately sampled variants. Directed evolution runs the same selection but reads only the enriched survivors and discards the failures.

Count variants before and after: winners rise, losers fall.

Ogden et al. (2019)

Letting Data Teach the Model

Machine-guided capsid design. The input changed from nine natural serotypes to a comprehensive measured landscape covering every single substitution across VP1. A schematic plot shows the fraction of a library that remains viable against substitutions from wild type: random mutagenesis collapses within a few substitutions while a model-designed library stays viable much further out. A loop underneath — measure, fit, design, measure again — notes that every round enlarges the training set.

The model learns what works, instead of us assuming.

Ogden et al. (2019); Bryant et al. (2021)

Promoters: Where a Gene Switches On

A promoter is DNA beside a gene where transcription starts.

Goal: gene on only in the target tissue, in as little DNA as possible.

Why:

  • wrong-tissue activity is unsafe
  • “on everywhere” can provoke immune attack

Specificity written into the DNA.

Gray et al. (2011)

Designed Promoters

Michael RobertsSynpromics → AskBio → Bayer · now Chromatin Bioscience

Screened libraries of short binding sites, then assembled the best into small, tissue-selective switches.

AMT-191: Fabry disease treatment. A liver-selective promoter drives the GLA gene.

First four patients: 27-208 times normal enzyme activity (company-reported, July 2025).

Designed, not borrowed.

uniQure (2025)

Why CpG Looks Like Danger

Why CpG reads as danger. Vertebrate DNA is CpG-poor and mostly methylated where CpG remains, while viral and bacterial DNA is CpG-rich and unmethylated, so unmethylated CpG inside an endosome is a signature of non-self. A five-step cascade follows: TLR9 fires in a plasmacytoid dendritic cell, type I interferon is released, conventional dendritic cells are licensed, anti-capsid CD8 T cells are primed, and transduced cells are cleared.

An innate alarm turns gene delivery into immune attack.

Faust et al. (2013); Mingozzi and High (2013)

Editing Viral Ends Safely

The ITR is a short stretch at each end of the viral DNA. It folds into a hairpin that the enzyme Rep recognises.

It is also rich in CpG.

Only 145 bases.

Faust et al. (2013)

Where This Goes

The limit is the dose ceiling: how much virus a patient can safely receive.

A better shell works at a lower dose.

Next steps:

  • human-tissue measurements
  • models across virus types
  • designs that avoid immunity

Biology sets the rules; the rest is search.

Ogden et al. (2019); Eid et al. (2024)

References

Breiman, Leo. 2001. “Random Forests.” Machine Learning 45 (1): 5–32. https://doi.org/10.1023/A:1010933404324.
Bryant, Drew H., Ali Bashir, Sam Sinai, et al. 2021. “Deep Diversification of an AAV Capsid Protein by Machine Learning.” Nature Biotechnology 39: 691–96. https://doi.org/10.1038/s41587-020-00793-4.
Cataldi, Marcela P., and Douglas M. McCarty. 2010. “Differential Effects of DNA Double-Strand Break Repair Pathways on Single-Strand and Self-Complementary Adeno-Associated Virus Vector Genomes.” Journal of Virology 84: 8673–82. https://doi.org/10.1128/JVI.00641-10.
Deverman, Benjamin E., Piers L. Pravdo, Bryan P. Simpson, et al. 2016. “Cre-Dependent Selection Yields AAV Variants for Widespread Gene Transfer to the Adult Brain.” Nature Biotechnology 34: 204–9. https://doi.org/10.1038/nbt.3440.
DiMattia, Michael A., Hyun-Joo Nam, Kim Van Vliet, et al. 2012. “Structural Insight into the Unique Properties of Adeno-Associated Virus Serotype 9.” Journal of Virology 86 (12): 6947–58. https://doi.org/10.1128/JVI.07232-11.
Dunbar, Cynthia E., Katherine A. High, J. Keith Joung, Donald B. Kohn, Keiya Ozawa, and Michel Sadelain. 2018. “Gene Therapy Comes of Age.” Science 359 (6372): eaan4672. https://doi.org/10.1126/science.aan4672.
Eid, Fatma-Elzahraa, Albert T. Chen, Ken Y. Chan, et al. 2024. “Systematic Multi-Trait AAV Capsid Engineering for Efficient Gene Delivery.” Nature Communications 15: 6602. https://doi.org/10.1038/s41467-024-50555-y.
Emancipator, Kenneth. 2020. “Keytruda and PD-L1: A Real-World Example of Co-Development of a Drug with a Predictive Biomarker.” The AAPS Journal 22: 35. https://doi.org/10.1208/s12248-020-00525-1.
Faust, Susan M., Peter Bell, Brett J. Cutler, et al. 2013. “CpG-Depleted Adeno-Associated Virus Vectors Evade Immune Detection.” Journal of Clinical Investigation 123 (7): 2994–3001. https://doi.org/10.1172/JCI68205.
Girod, Anne, Christiane E. Wobus, Zoltán Zádori, et al. 2002. “The VP1 Capsid Protein of Adeno-Associated Virus Type 2 Is Carrying a Phospholipase A2 Domain Required for Virus Infectivity.” Journal of General Virology 83 (5): 973–78. https://doi.org/10.1099/0022-1317-83-5-973.
Goldberg, Sarah B., Scott N. Gettinger, Amit Mahajan, et al. 2016. “Pembrolizumab for Patients with Melanoma or Non-Small-Cell Lung Cancer and Untreated Brain Metastases: Early Analysis of a Non-Randomised, Open-Label, Phase 2 Trial.” The Lancet Oncology 17 (7): 976–83. https://doi.org/10.1016/S1470-2045(16)30053-5.
Gray, Steven J., Sandra B. Foti, Joshua W. Schwartz, et al. 2011. “Optimizing Promoters for Recombinant Adeno-Associated Virus-Mediated Gene Expression in the Peripheral and Central Nervous System Using Self-Complementary Vectors.” Human Gene Therapy 22 (9): 1143–53. https://doi.org/10.1089/hum.2010.245.
Grimm, Dirk, Joyce S. Lee, Lora Wang, et al. 2008. “In Vitro and in Vivo Gene Therapy Vector Evolution via Multispecies Interbreeding and Retargeting of Adeno-Associated Viruses.” Journal of Virology 82 (12): 5887–911. https://doi.org/10.1128/JVI.00254-08.
Hinderer, Christian, Nathan Katz, Elizabeth L. Buza, et al. 2018. “Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN.” Human Gene Therapy 29 (3): 285–98. https://doi.org/10.1089/hum.2018.015.
Kotin, Robert M., Michele Siniscalco, R. Jude Samulski, et al. 1990. “Site-Specific Integration by Adeno-Associated Virus.” Proceedings of the National Academy of Sciences 87 (6): 2211–15. https://doi.org/10.1073/pnas.87.6.2211.
Manno, Catherine S., Glenn F. Pierce, Valder R. Arruda, et al. 2006. “Successful Transduction of Liver in Hemophilia by AAV-Factor IX and Limitations Imposed by the Host Immune Response.” Nature Medicine 12: 342–47. https://doi.org/10.1038/nm1358.
Mendell, Jerry R., Perry B. Shieh, Craig M. McDonald, et al. 2023. “Expression of SRP-9001 Dystrophin and Stabilization of Motor Function up to 2 Years Post-Treatment with Delandistrogene Moxeparvovec Gene Therapy in Individuals with Duchenne Muscular Dystrophy.” Frontiers in Cell and Developmental Biology 11: 1167762. https://doi.org/10.3389/fcell.2023.1167762.
Mikos, Georgios, Weitong Chen, and Junghae Suh. 2021. “Machine Learning Identification of Capsid Mutations to Improve AAV Production Fitness.” bioRxiv, ahead of print. https://doi.org/10.1101/2021.06.15.447941.
Mingozzi, Federico, and Katherine A. High. 2013. “Immune Responses to AAV Vectors: Overcoming Barriers to Successful Gene Therapy.” Blood 122 (1): 23–36. https://doi.org/10.1182/blood-2013-01-306647.
Nakai, Hiroyuki, Stephen R. Yant, Theresa A. Storm, Sally Fuess, Leonard Meuse, and Mark A. Kay. 2001. “Extrachromosomal Recombinant Adeno-Associated Virus Vector Genomes Are Primarily Responsible for Stable Liver Transduction in Vivo.” Journal of Virology 75 (15): 6969–76. https://doi.org/10.1128/JVI.75.15.6969-6976.2001.
Ng, Andrew Y., and Michael I. Jordan. 2001. “On Discriminative Vs. Generative Classifiers: A Comparison of Logistic Regression and Naive Bayes.” Advances in Neural Information Processing Systems 14.
Ogden, Pierce J., Eric D. Kelsic, Sam Sinai, and George M. Church. 2019. “Comprehensive AAV Capsid Fitness Landscape Reveals a Viral Gene and Enables Machine-Guided Design.” Science 366 (6469): 1139–43. https://doi.org/10.1126/science.aaw2900.
Polack, Fernando P., Stephen J. Thomas, Nicholas Kitchin, et al. 2020. “Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.” New England Journal of Medicine 383: 2603–15. https://doi.org/10.1056/NEJMoa2034577.
Romero, Philip A., and Frances H. Arnold. 2009. “Exploring Protein Fitness Landscapes by Directed Evolution.” Nature Reviews Molecular Cell Biology 10: 866–76. https://doi.org/10.1038/nrm2805.
Samulski, R. Jude, and Nicholas Muzyczka. 2014. “AAV-Mediated Gene Therapy for Research and Therapeutic Purposes.” Annual Review of Virology 1: 427–51. https://doi.org/10.1146/annurev-virology-031413-085355.
Shen, Shen, Kelli D. Bryant, Sarah M. Brown, Scott H. Randell, and Aravind Asokan. 2011. “Terminal N-Linked Galactose Is the Primary Receptor for Adeno-Associated Virus 9.” Journal of Biological Chemistry 286 (15): 13532–40. https://doi.org/10.1074/jbc.M110.210922.
Sonntag, Florian, Kristin Schmidt, and Jürgen A. Kleinschmidt. 2010. “A Viral Assembly Factor Promotes AAV2 Capsid Formation in the Nucleolus.” Proceedings of the National Academy of Sciences 107 (22): 10220–25. https://doi.org/10.1073/pnas.1001673107.
Summerford, Candace, and R. Jude Samulski. 1998. “Membrane-Associated Heparan Sulfate Proteoglycan Is a Receptor for Adeno-Associated Virus Type 2 Virions.” Journal of Virology 72 (2): 1438–45. https://doi.org/10.1128/JVI.72.2.1438-1445.1998.
uniQure. 2025. uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in Alpha-Gal a Enzyme Activity in Patients with Fabry Disease. https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-initial-amt-191-phase-iiia-data-showing.
Urabe, Masashi, Chunping Ding, and Robert M. Kotin. 2002. “Insect Cells as a Factory to Produce Adeno-Associated Virus Type 2 Vectors.” Human Gene Therapy 13 (16): 1935–43. https://doi.org/10.1089/10430340260355347.
U.S. Food and Drug Administration. 2026a. Approved Cellular and Gene Therapy Products. https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products.
U.S. Food and Drug Administration. 2026b. FDA Approves First-Ever Gene Therapy for Treatment of Genetic Hearing Loss Under National Priority Voucher Program. https://www.fda.gov/news-events/press-announcements/fda-approves-first-ever-gene-therapy-treatment-genetic-hearing-loss-under-national-priority-voucher.
Voysey, Merryn, Sue Ann Costa Clemens, Shabir A. Madhi, et al. 2021. “Safety and Efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2.” The Lancet 397 (10269): 99–111. https://doi.org/10.1016/S0140-6736(20)32661-1.
Xie, Qing, Wenman Bu, Shaswati Bhatia, et al. 2002. “The Atomic Structure of Adeno-Associated Virus (AAV-2), a Vector for Human Gene Therapy.” Proceedings of the National Academy of Sciences 99 (16): 10405–10. https://doi.org/10.1073/pnas.162250899.
Zanta-Boussif, M. A., S. Charrier, A. Brice-Ouzet, et al. 2009. “Validation of a Mutated PRE Sequence Allowing High and Sustained Transgene Expression While Abrogating WHV-X Protein Synthesis: Application to the Gene Therapy of WAS.” Gene Therapy 16 (5): 605–19. https://doi.org/10.1038/gt.2009.3.

Credits

Structures — RCSB PDB. AAV2 1LP3, AAV9 3UX1. Icosahedral assemblies expanded in-browser from the deposited asymmetric units.

Software — three.js and NGL Viewer, both MIT, vendored into this repository.

Diagrams — drawn for this deck; MIT with the rest of the source.

Portraits — via Wikimedia Commons. CC BY-SA 4.0:

  • Uğur Şahin, Özlem Türeci — © BioNTech SE
  • Katalin Karikó — © University of Szeged

Public domain: Jimmy Carter — Lauren Gerson, LBJ Presidential Library, 2014.

Plate — Duchenne de Boulogne (1868), public domain.

Three Parts, Three Problems — AAV2 capsid surface: Jazzlw, CC BY-SA 4.0, derived from PDB 1LP3, via Wikimedia Commons. Promoter and ITR figures are from the original talk; their sources are not recorded here.

Vaccine 1 and 2 — chimpanzee: Mira Meijer, Burgers’ Zoo, CC BY-SA 4.0; delivery van (Ford Transit Connect): Winnebaggo, CC0; both via Wikimedia Commons. The lipid-nanoparticle diagram is from the original talk; its source is not recorded here.

HeLa — statue of Henrietta Lacks, 14GTR, CC BY-SA 4.0; HeLa cell micrograph, NIH, public domain. Via Wikimedia Commons.

AAV successes — retina photograph: Christian Hamel, CC BY 2.0; motor-unit diagram: Daniel Walsh and Alan Sved, CC BY-SA 4.0; clotting-factor vials: JJEv810, CC BY-SA 4.0; ear anatomy: Lars Chittka and Axel Brockmann, CC BY 2.5. All via Wikimedia Commons.

No photograph of an identifiable patient appears here without their own disclosure. President Carter announced his diagnosis and his treatment publicly, himself. The Duchenne figure is an 1868 engraving, not a photograph of a living child.

Questions